Rilonacept

Rilonacept (marketed under the tradename Arcalyst), is a dimeric fusion protein for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It was given an "Orphan Drug" status by the United States Food and Drug Administration.

It was approved by the FDA on February 2008.